Skip to main content
. 2021 Aug 28;35(4):203–213. doi: 10.1007/s40290-021-00397-6
The Emergency Use Authorization (EUA) acted as a critical regulatory pathway for therapeutics and vaccines throughout the Coronavirus Disease 2019 (COVID-19) pandemic.
The EUA process demonstrates the dynamic nature of scientific review practices as characterized by emergency authorizations, expansion of the authorizations, and withdrawal of previously authorized products.
EUAs were of critical utility in countering the pandemic and proved a remarkable regulatory framework for a monumental pharmaceutical achievement.